NEW YORK, NY / ACCESS Newswire / March 7, 2025 / If you suffered a loss on your GSK plc (NYSE ... Class Action Services' Top 50 Report as one of the top securities litigation firms in the United ...

The stock climbed 5.9% in early trading, making it the top performer on the FTSE 100 and on track for its biggest one-day gain since 2022. GSK increased its 2031 sales target to more than £40 ...

GSK noted that analyst sentiment has been turning "more negative" as patents for medicines, including its HIV treatment dolutegravir, were set to expire in the next few years. GSK said it had made ...

GSK (GSK) plc announces the commencement of its share buyback program, as announced in its 2024 full year results announcement published on 5 February 2025. The Program will return an additional ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine ... s meningococcal vaccines Trumenba and Nimenrix, which together made around $300 million in 2023, and started shipping ...

GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical ... portfolios of Bristol-Myers Squibb (BMS) (together with its local manufacturing facility ...

“The expansion of lab space here to include vaccines R&D will help us bring together expertise working ... the employee and business needs." GSK drops one potential 'functional cure' for hep ...

To stream WGRZ on your phone, you need the WGRZ app.

LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...

The market was pleased with the recent earnings report from GSK plc (LON:GSK), despite the ... and found that unusual items are very often one-off in nature. And that's hardly a surprise given ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.